Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 104105, 7 pages
http://dx.doi.org/10.1100/2012/104105
Review Article

The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development

Mood Disorders Research Program, Butler Hospital and Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02906, USA

Received 26 January 2012; Accepted 28 February 2012

Academic Editors: A. Czurko, S. M. Dursun, H. Luddens, and P. Stratta

Copyright © 2012 Noah S. Philip et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. H. Trivedi, A. J. Rush, S. R. Wisniewski et al., “Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice,” American Journal of Psychiatry, vol. 163, no. 1, pp. 28–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. N. S. Philip, L. L. Carpenter, A. R. Tyrka, and L. H. Price, “Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature,” Psychopharmacology, vol. 212, no. 1, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Sabri, K. Kendziorra, H. Wolf, H. J. Gertz, and P. Brust, “Acetylcholine receptors in dementia and mild cognitive impairment,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. S30–S45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. E. L. M. Ochoa and J. Lasalde-Dominicci, “Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking,” Cellular and Molecular Neurobiology, vol. 27, no. 5, pp. 609–639, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Cincotta, M. S. Yorek, T. M. Moschak, S. R. Lewis, and J. S. Rodefer, “Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction,” Current Opinion in Investigational Drugs, vol. 9, no. 1, pp. 47–56, 2008. View at Google Scholar · View at Scopus
  6. I. Bacher, B. Wu, D. R. Shytle, and T. P. George, “Mecamylamine a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders,” Expert Opinion on Pharmacotherapy, vol. 10, no. 16, pp. 2709–2721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. X. Albuquerque, E. F. R. Pereira, M. Alkondon, and S. W. Rogers, “Mammalian nicotinic acetylcholine receptors: from structure to function,” Physiological Reviews, vol. 89, no. 1, pp. 73–120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Gotti, M. Zoli, and F. Clementi, “Brain nicotinic acetylcholine receptors: native subtypes and their relevance,” Trends in Pharmacological Sciences, vol. 27, no. 9, pp. 482–491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Chen, L. M. Broad, K. G. Phillips, and R. Zwart, “Partial agonists for alpha4beta2 nicotinic receptors stimulate dopamine neuron firing with relatively enhanced maximal effects,” British Journal of Pharmacology, vol. 165, no. 4, pp. 1006–1016, 2012. View at Publisher · View at Google Scholar
  10. X. Li, D. G. Rainnie, R. W. McCarley, and R. W. Greene, “Presynaptic nicotinic receptors facilitate monoaminergic transmission,” Journal of Neuroscience, vol. 18, no. 5, pp. 1904–1912, 1998. View at Google Scholar · View at Scopus
  11. S. Mihailescu, R. Guzman-Marin, M. C Dominguez, and R. Drucker-Colin, “Mechanisms of nicotine actions on dorsal raphe serotoninergic neurons,” European Journal of Pharmacology, vol. 452, no. 1, pp. 77–82, 2002. View at Google Scholar
  12. S. Mihailescu, M. Palomero-Rivero, P. Meade-Huerta, A. Maza-Flores, and R. Drucker-Colín, “Effects of nicotine and mecamylamine on rat dorsal raphe neurons,” European Journal of Pharmacology, vol. 360, no. 1, pp. 31–36, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. B. W. Dunlop and C. B. Nemeroff, “The role of dopamine in the pathophysiology of depression,” Archives of General Psychiatry, vol. 64, no. 3, pp. 327–337, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Z. Guo, E. M. Sorenson, and V. A. Chiappinelli, “Cholinergic modulation of non-N-methyl-D-aspartic acid glutamatergic transmission in the chick ventral lateral geniculate nucleus.,” Neuroscience, vol. 166, no. 2, pp. 604–614, 2010. View at Google Scholar · View at Scopus
  15. H. Okuda, S. Shioda, Y. Nakai, H. Nakayama, M. Okamoto, and T. Nakashima, “The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat,” Neuroscience Letters, vol. 161, no. 2, pp. 183–186, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Raber, G. F. Koob, and F. E. Bloom, “Interleukin-2 (il-2) induces corticotropin-releasing factor (crf) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response,” Journal of Pharmacology and Experimental Therapeutics, vol. 272, no. 2, pp. 815–824, 1995. View at Google Scholar · View at Scopus
  17. A. H. Miller, V. Maletic, and C. L. Raison, “Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression,” Biological Psychiatry, vol. 65, no. 9, pp. 732–741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. D. Shytle, T. Mori, K. Townsend et al., “Cholinergic modulation of microglial activation by α7 nicotinic receptors,” Journal of Neurochemistry, vol. 89, no. 2, pp. 337–343, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Gallowitsch-Puerta and V. A. Pavlov, “Neuro-immune interactions via the cholinergic anti-inflammatory pathway,” Life Sciences, vol. 80, no. 24-25, pp. 2325–2329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. T. Andreasen and J. P. Redrobe, “Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests,” Behavioural Brain Research, vol. 197, no. 1, pp. 150–156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. V. J. Djuric, E. Dunn, D. H. Overstreet, A. Dragomir, and M. Steiner, “Antidepressant effect of ingested nicotine in female rats of Flinders resistant and sensitive lines,” Physiology & Behavior, vol. 67, no. 4, pp. 533–537, 1999. View at Google Scholar
  22. J. Semba, C. Mataki, S. Yamada, M. Nankai, and M. Toru, “Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats,” Biological Psychiatry, vol. 43, no. 5, pp. 389–391, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Tizabi, D. H. Overstreet, A. H. Rezvani et al., “Antidepressant effects of nicotine in an animal model of depression,” Psychopharmacology, vol. 142, no. 2, pp. 193–199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. R. D. Porsolt, M. Le Pichon, and M. Jalfre, “Depression: a new animal model sensitive to antidepressant treatments,” Nature, vol. 266, no. 5604, pp. 730–732, 1977. View at Google Scholar · View at Scopus
  25. L. Steru, R. Chermat, B. Thierry, and P. Simon, “The tail suspension test: a new method for screening antidepressants in mice,” Psychopharmacology, vol. 85, no. 3, pp. 367–370, 1985. View at Google Scholar · View at Scopus
  26. R. J. Salin-Pascual, “Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients,” Revista De Investigacion Clinica, vol. 54, no. 1, pp. 36–40, 2002. View at Google Scholar · View at Scopus
  27. F. J. McClernon, F. B. Hiott, E. C. Westman, J. E. Rose, and E. D. Levin, “Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial,” Psychopharmacology, vol. 189, no. 1, pp. 125–133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. L. Gentry and R. J. Lukas, “Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure,” Curr Drug Target Cns Neurol Disord, vol. 1, no. 4, pp. 359–385, 2002. View at Google Scholar · View at Scopus
  29. K. G. Paradiso and J. H. Steinbach, “Nicotine is highly effective at producing desensitization of rat α4β2neuronal nicotinic receptors,” Journal of Physiology, vol. 553, no. 3, pp. 857–871, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. R. D. Shytle, A. A. Silver, R. J. Lukas, M. B. Newman, D. V. Sheehan, and P. R. Sanberg, “Nicotinic acetylcholine receptors as targets for antidepressants,” Molecular Psychiatry, vol. 7, no. 6, pp. 525–535, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. S. Mineur and M. R. Picciotto, “Biological basis for the co-morbidity between smoking and mood disorders,” Journal of Dual Diagnosis, vol. 5, no. 2, pp. 122–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. R. Picciotto, N. A. Addy, Y. S. Mineur, and D. H. Brunzell, “It is not “either/or”: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood,” Progress in Neurobiology, vol. 84, no. 4, pp. 329–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Bacher, R. Rabin, A. Woznica, K. A. Sacco, and T. P. George, “Nicotinic receptor mechanisms in neuropsychiatric disorders: therapeutic implications,” Primary Psychiatry, vol. 17, no. 1, pp. 35–41, 2010. View at Google Scholar · View at Scopus
  34. R. D. Shytle, A. A. Silver, K. H. Sheehan, D. V. Sheehan, and P. R. Sanberg, “Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine,” Depression and Anxiety, vol. 16, no. 3, pp. 89–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Popik, E. Kozela, and M. Krawczyk, “Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram,” British Journal of Pharmacology, vol. 139, no. 6, pp. 1196–1202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. R. L. Rabenstein, B. J. Caldarone, and M. R. Picciotto, “The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice,” Psychopharmacology, vol. 189, no. 3, pp. 395–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. B. J. Caldarone, A. Harrist, M. A. Cleary, R. D. Beech, S. L. King, and M. R. Picciotto, “High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation,” Biological Psychiatry, vol. 56, no. 9, pp. 657–664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. T. Andreasen, G. M. Olsen, O. Wiborg, and J. P. Redrobe, “Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests,” Journal of Psychopharmacology, vol. 23, no. 7, pp. 797–804, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. S. Mineur, O. Somenzi, and M. R. Picciotto, “Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male c57bl/6j mice,” Neuropharmacology, vol. 52, no. 5, pp. 1256–1262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. M. Lippiello, J. S. Beaver, G. J. Gatto et al., “Tc-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity,” CNS Neuroscience and Therapeutics, vol. 14, no. 4, pp. 266–277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. Association AP, Diagnostic and Statistical Manual of Mental Disorders, 4th, Washington, DC, USA.
  42. T. P. George, K. A. Sacco, J. C. Vessicchio, A. H. Weinberger, and R. D. Shytle, “Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 340–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. A. Dani and R. A. Harris, “Nicotine addiction and comorbidity with alcohol abuse and mental illness,” Nature Neuroscience, vol. 8, no. 11, pp. 1465–1470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. Targacept, http://www.targacept.com/wt/page/tc_5214.
  45. P. Tutka and W. Zatoński, “Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy,” Pharmacological Reports, vol. 58, no. 6, pp. 777–798, 2006. View at Google Scholar · View at Scopus
  46. Y. S. Mineur, C. Eibl, G. Young et al., “Cytisine-based nicotinic partial agonists as novel antidepressant compounds,” Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 1, pp. 377–386, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. C. H. Beck and H. C. Fibiger, “Chronic desipramine alters stress-induced behaviors and regional expression of the immediate early gene, c-fos,” Pharmacol Biochem Behav, vol. 51, no. 2-3, pp. 331–338, 1995. View at Google Scholar
  48. D. A. Slattery, J. A. Morrow, A. L. Hudson, D. R. Hill, D. J. Nutt, and B. Henry, “Comparison of alterations in c-fos and egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds,” Neuropsychopharmacology, vol. 30, no. 7, pp. 1278–1287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. R. West, W. Zatonski, M. Cedzynska et al., “Placebo-controlled trial of cytisine for smoking cessation,” The New England Journal of Medicine, vol. 365, no. 13, pp. 1193–1200, 2011. View at Google Scholar
  50. G. A. Bentley and J. Starr, “The antinociceptive action of some β-adrenoceptor agonists in mice,” British Journal of Pharmacology, vol. 88, no. 3, pp. 515–521, 1986. View at Google Scholar · View at Scopus
  51. J. W. Coe, P. R. Brooks, M. G. Vetelino et al., “Varenicline: an alpha;4β2 nicotinic receptor partial agonist for smoking cessation,” Journal of Medicinal Chemistry, vol. 48, no. 10, pp. 3474–3477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Rollema, V. Guanowsky, Y. S. Mineur et al., “Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect,” European Journal of Pharmacology, vol. 605, no. 1–3, pp. 114–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. J. R. Turner, L. M. Castellano, and J. A. Blendy, “Nicotinic partial agonists varenicline and sazetidine-a have differential effects on affective behavior,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 2, pp. 665–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. D. E. Jorenby, J. T. Hays, N. A. Rigotti et al., “Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial,” Journal of the American Medical Association, vol. 296, no. 1, pp. 56–63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Gonzales, S. I. Rennard, M. Nides et al., “Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial,” Journal of the American Medical Association, vol. 296, no. 1, pp. 47–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Patterson, C. Jepson, A. A. Strasser et al., “Varenicline improves mood and cognition during smoking abstinence,” Biological Psychiatry, vol. 65, no. 2, pp. 144–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. N. S. Philip, L. L. Carpenter, A. R. Tyrka, L. B. Whiteley, and L. H. Price, “Varenicline augmentation in depressed smokers: an 8-week, open-label study,” Journal of Clinical Psychiatry, vol. 70, no. 7, pp. 1026–1031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. P. Kozikowski, J. Brek Eaton, K. M. Bajjuri et al., “Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (amop-h-oh) for possible use in depression,” Chemmedchem, vol. 4, no. 8, pp. 1279–1291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. B. J. Caldarone, D. Wang, N. E. Paterson et al., “Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-i-a85380,” Psychopharmacology, vol. 217, pp. 199–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Freedman, “Exacerbation of schizophrenia by varenicline,” American Journal of Psychiatry, vol. 164, no. 8, p. 1269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. I. Kohen and N. Kremen, “Varenicline-induced manic episode in a patient with bipolar disorder [8],” American Journal of Psychiatry, vol. 164, no. 8, pp. 1269–1270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. M. K. Popkin, “Exacerbation of recurrent depression as a result of treatment with varenicline,” American Journal of Psychiatry, vol. 165, no. 6, p. 774, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. T. J. Moore, C. D. Furberg, J. Glenmullen, J. T. Maltsberger, and S. Singh, “Suicidal behavior and depression in smoking cessation treatments,” PLoS One, vol. 6, no. 11, article e27016, 2011. View at Google Scholar
  64. S. Tonstad, S. Davies, M. Flammer, C. Russ, and J. Hughes, “Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis,” Drug Safety, vol. 33, no. 4, pp. 289–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. J. B. McClure, G. E. Swan, L. Jack et al., “Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline,” Journal of General Internal Medicine, vol. 24, no. 5, pp. 563–569, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. J. A. Stapleton, L. Watson, L. I. Spirling et al., “Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness,” Addiction, vol. 103, no. 1, pp. 146–154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Gunnell, D. Irvine, L. Wise, C. Davies, and R. M. Martin, “Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database,” BMJ, vol. 339, article b3805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. U.S. Food and Drug Administration, “FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events,” http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm.
  69. J. R. Hughes, “Depression during tobacco abstinence,” Nicotine and Tobacco Research, vol. 9, no. 4, pp. 443–446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. D. J. Anderson, J. Malysz, J. H. Gronlien et al., “Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination,” Biochemical Pharmacology, vol. 78, no. 7, pp. 844–851, 2009. View at Google Scholar
  71. H. Rollema, A. Shrikhande, K. M. Ward et al., “Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence,” British Journal of Pharmacology, vol. 160, no. 2, pp. 334–345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Tonstad, I. Holme, and P. Tønnesen, “Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial,” Nicotine and Tobacco Research, vol. 13, no. 1, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Xiao, H. Fan, J. L. Musachio et al., “Sazetidine-a, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them,” Molecular Pharmacology, vol. 70, no. 4, pp. 1454–1460, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Liu, L. F. Yu, J. B. Eaton et al., “Discovery of isoxazole analogues of sazetidine-A as selective alpha4beta2-nicotinic acetylcholine receptor partial agonists for the treatment of depression,” Journal of Medicinal Chemistry, vol. 54, no. 20, pp. 7280–7288, 2011. View at Google Scholar
  75. L. F. Yu, W. Tuckmantel, J. B. Eaton et al., “Identification of Novel alpha4beta2-Nicotinic Acetylcholine Receptor (nAChR) agonists based on an isoxazole ether scaffold that cemonstrate antidepressant-like activity,” Journal of Medicinal Chemistry, vol. 55, no. 2, pp. 812–823, 2012. View at Google Scholar
  76. H. Zhang, W. Tuckmantel, J. B. Eaton et al., “Chemistry and behavioral studies identify chiral cyclopropanes as selective alpha4beta2-Nicotinic Acetylcholine receptor partial agonists exhibiting an antidepressant profile,” Journal of Medicinal Chemistry, vol. 55, no. 2, pp. 717–724, 2012. View at Google Scholar
  77. L. Maggi, E. Palma, R. Miledi, and F. Eusebi, “Effects of fluoxetine on wild and mutant neuronal α7 nicotinic receptors,” Molecular Psychiatry, vol. 3, no. 4, pp. 350–355, 1998. View at Google Scholar · View at Scopus
  78. J. T. Andreasen, E. O. Nielsen, J. K. Christensen et al., “Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test,” Journal of Psychopharmacology, vol. 25, no. 10, pp. 1347–1356, 2011. View at Google Scholar
  79. J. T. Andreasen, J. P. Redrobe, and E. O. Nielsen, “Combined alpha7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987,” Pharmacology Biochemistry and Behavior, vol. 100, no. 3, pp. 624–629, 2012. View at Google Scholar
  80. V. Voikar, S. Koks, E. Vasar, and H. Rauvala, “Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies,” Physiology & Behavior, vol. 72, no. 1-2, pp. 271–281, 2001. View at Google Scholar
  81. D. P. Walker, D. G. Wishka, D. W. Piotrowski et al., “Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists,” Bioorganic and Medicinal Chemistry, vol. 14, no. 24, pp. 8219–8248, 2006. View at Publisher · View at Google Scholar · View at Scopus